Patents by Inventor Derek A. Prater

Derek A. Prater has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Buprenorphine-wafer for drug substitution therapy
    Publication number: 20190216797
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 18, 2019
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • BUPRENORPHINE WAFER FOR DRUG SUBSTITUTION THERAPY
    Publication number: 20180008595
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 11, 2018
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9861628
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 9, 2018
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9763931
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 19, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Buprenorphine-Wafer for Drug Substitution Therapy
    Publication number: 20170157062
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 8, 2017
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-wafer for drug substitution therapy
    Publication number: 20160235738
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • BUPRENORPHINE WAFER FOR DRUG SUBSTITUTION THERAPY
    Publication number: 20160235739
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9370512
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 21, 2016
    Assignee: PURDUE PHARMA L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Buprenorphine-Wafer for Drug Substitution Therapy
    Publication number: 20150328143
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: July 15, 2015
    Publication date: November 19, 2015
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9101625
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: August 11, 2015
    Assignee: PURDUE PHARMA L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Buprenorphine-Wafer for Drug Substitution Therapy
    Publication number: 20150025102
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 22, 2015
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-Wafer for Drug Substitution Therapy
    Publication number: 20100087470
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: August 29, 2007
    Publication date: April 8, 2010
    Applicant: EURO-CELTIQUE S.A.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Spheroid formulation
    Patent number: 5622722
    Abstract: A pharmaceutical composition comprising spheroids comprising a water-soluble active ingredient or a pharmaceutically acceptable salt thereof, microcrystalline cellulose and a sugar. Preferably the active ingredient is hydromorphone hydrochloride and the sugar is lactose. Surprisingly the incorporation of a sugar improves the dissolution rate of the spheroid formulation instead of reducing the dissolution rate by competing with the active ingredient for solubilization.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: April 22, 1997
    Assignee: Euro-Celtique, S.A.
    Inventors: Trevor J. Knott, Sandra T. A. Malkowska, Philip J. Neale, Stewart T. Leslie, Ronald B. Miller, Derek A. Prater
  • Pharmaceutical spheroid formulation
    Patent number: 5601845
    Abstract: A controlled release composition including spheroid cores of diltiazem. or a pharmaceutically acceptable salt thereof and optionally a spheronizing agent, the cores being coated with a controlled release layer, and a method of manufacturing the same, is disclosed. The spheronizing agent when present is preferably microcrystalline cellulose. Ethylcellulose is a preferred release coating. The controlled release coating preferably contains a plasticizer, a surfactant and a tack-modifier.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: February 11, 1997
    Assignee: Euro-Celtique, S.A.
    Inventors: Ian R. Buxton, Helen Critchley, Stewart T. Leslie, Derek A. Prater, Ronald B. Miller, Sandra T. A. Malkowska
  • Controlled release formulation
    Patent number: 5591452
    Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.
    Type: Grant
    Filed: May 10, 1994
    Date of Patent: January 7, 1997
    Assignee: Euro-Celtique, S.A.
    Inventors: Ronald B. Miller, Stewart T. Leslie, Sandra T. A. Malkowska, Kevin J. Smith, Walter Wimmer, Horst Winkler, Udo Hahn, Derek A. Prater
  • Laxative compositions
    Patent number: 5525355
    Abstract: A method for the manufacture of a laxative composition in dosage unit form which comprises the steps of melting a normally solid stool softener; dispersing and/or dissolving a stimulant laxative compound in the molten stool softener and mixing to obtain a uniform mixture; filling the molten dispersion into hard gelatin capsule shells; and allowing the capsules to cool and the melt or dispersion to solidify.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: June 11, 1996
    Assignee: Euro-Celtique, S.A.
    Inventors: Adrian Brown, Sandra T. A. Malkowska, Stewart T. Leslie, Derek A. Prater, Ronald B. Miller
  • Diltiazem pharmaceutical spheroid formulation
    Patent number: 5508044
    Abstract: A solid oral dosage form comprising diltiazem (or a pharmaceutically acceptable salt thereof) in controlled release form and hydrochlorothiazide in immediate release form. Preferably, the controlled release component comprises a plurality of spheroids comprising diltiazem and a spheronizing agent.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: April 16, 1996
    Assignee: Euro-Celtique, S.A.
    Inventors: Ian R. Buxton, Adrian Brown, Helen Critchley, Stewart T. Leslie, Sandra T. A. Malkowska, Derek A. Prater, Ronald B. Miller
  • Phenothrin shampoo
    Patent number: 5112515
    Abstract: The invention relates to a lousicidal shampoo composition of phenothrin as lousicidal agent distributed in a shampoo base of water and one or more surface active agents, the shampoo containing as antimicrobial preservative 2-bromo-2-nitropropane-1,3-diol alone or in combination with 2,4-dichlorobenzyl alcohol.
    Type: Grant
    Filed: February 5, 1991
    Date of Patent: May 12, 1992
    Assignee: Euroceltique, S.A.
    Inventors: Ian R. Buxton, Sandra T. A. Malkowska, Derek A. Prater, Deborah L. Singh, Stewart T. Leslie, Ronald B. Miller
  • Pharmaceutical ion exchange resin composition
    Patent number: 5071646
    Abstract: An ion exchange resin composition which is readily dispersible in water is provided. This resin composition comprises a granulated ion exchange resin, a pharmacologically active ingredient bound thereto with a sugar or sugar alcohol, and a sufficient amount of water, alcohol or aqueous alcohol to facilitate granulation. The invention further comprises a method for the preparation of such ion exchange resin composition.
    Type: Grant
    Filed: November 9, 1989
    Date of Patent: December 10, 1991
    Assignee: Euroceltique, S.A.
    Inventors: Sandra T. A. Malkowska, Ian R. Buxton, Derek A. Prater, Alison A. Norman